NCT04295941

Long-term Study With Trazodone Once-a-Day

Long-term Treatment With Trazodone Once-a-Day (TzOAD) in Patients With MDD: an Observational, Prospective Study

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 200 (actual)
• Sponsor: Aziende Chimiche Riunite Angelini Francesco S.p.A · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The aim of the present observational study is to assess the clinical response, functional impairment and quality of life in outpatients with Major Depressive Disorder who demonstrated an initial positive response to the acute treatment with Trazodone once-a-day monotherapy, for up to 24 weeks.

Detailed description

This is an observational, prospective, single group, multicentre, international study. The present study is planned to assess, in a real-world setting, the long-term clinical response, functional impairment and quality of life in outpatients with Major Depressive Disorder who, according to the physician's judgment, have responded to the acute monotherapy (6 to 8 weeks of treatment) with Trazodone once-a-day and are eligible to continue Trazodone once-a-day monotherapy according to clinical practice.

Conditions

• Major Depressive Disorder

Interventions

Type	Name	Description
DRUG	TraZODone Hydrochloride 300 MG	Oral administration of Trazodone once-a-day.

Timeline

• Start date: 2020-06-23
• Primary completion: 2021-11-16
• Completion: 2021-11-16
• First posted: 2020-03-05
• Last updated: 2022-09-21

Locations

1 site across 1 country: Bulgaria